Document is current
Any future updates will be listed below
-
Authors
Lai, Nian-Shiuan
Lin, Chun-Jung
Kuo, Ching-Hua
Peng, Yu-Fong
Tang, Sung-Chun
Huang, Chih-Fen
Lin, Shin-Yi https://orcid.org/0000-0002-7319-6644
Lin, Shu-Wen
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05333666 at ClinicalTrials.govDocuments that mention this clinical trial
Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation
https://doi.org/10.1007/s40262-026-01650-4
-
Funding
Funding for this research was provided by:
National Science and Technology Council (112-2314-B-002-313)
National Taiwan University Hospital (114-S0112)
- License Information
-
More Information
Article History
Received: 1 October 2025
Accepted: 22 April 2026
First Online: 17 May 2026
Declarations
:
: Nian-Shiuan Lai, Chun-Jung Lin, Ching-Hua Kuo, Yu-Fong Peng, Sung-Chun Tang, Chih-Fen Huang, Shin-Yi Lin, and Shu-Wen Lin declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
: Nian-Shiuan Lai, Shin-Yi Lin, and Shu-Wen Lin contributed to the conceptualization, methodology, investigation, and formal analysis. Shin-Yi Lin drafted the original manuscript, and all the other authors critically reviewed and edited of the manuscript. Ching-Hua Kuo contributed to the resources for concentration analysis. Sung-Chun Tang and Chih-Feng Huang contributed to the conceptualization and methodology of the investigation. Shin-Yi Lin contributed to funding acquisition.
: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
: The study protocol was approved by the International Ethics Committee of NTUH (No. 202201014RINB) and registered in the ClinicalTrials.gov database (NCT05333666).
: All participants provided written informed consent prior to enrollment in the study.
: Not applicable.
: Not applicable.
